Introduction
Type 1 Diabetes mellitus (T1DM) is an autoimmune disease whose complex etiology is not completely understood. It is recognized to be caused by both genetic and environmental components. During T1DM pathogenesis macrophages and lymphocytes infiltrate the islets. Thereby, the intensity of the β-cell destructive process is modulated by the interaction of a large number of susceptibility genes and both known (nutritional factors and viral infection) and unknown environmental factors [1] .
Activated macrophages produce proinflammmatory cytokines that can destroy pancreatic β-cells.
Cytokines were therefore proposed as mediators of β-cell death in vivo [2] , that is confirmed in NOD mice for TNF-α [3] . It was known that G-238A and G-308A SNPs in TNF-α promoter have a direct effect on transcriptional activity, where the A allele for both loci interprets high cytokineproducing variant. Genetically determined interindividual variation in the production of this cytokine could predispose certain individuals with the risk genotype to develop T1DM [4] .
The critical events leading to loss of T cell tolerance to pancreatic b-cells are still largely unknown. It seems that inefficient thymic negative selection increases the frequency of specific CD4+ and CD8+ T cells in the periphery, while a defective peripheral tolerance contributes to the expansion and differentiation of autoreactive Tcells [5] . Effector functions of T cells are regulated by the activation of intracellular signaling pathways in response to triggering of the T-cell receptor. Lymphoid-specific phosphatase (Lyp), encoded by the PTPN22 gene, has direct role in setting thresholds for signaling through T-cell receptor. Thereby, the 1858T gene variant (not 1858C) is a gain-of-function form of the enzyme with significantly higher phosphatase activity and a dominant suppressing effect on receptor signaling [6, 7] .
Taking these facts in consideration we have several reasons to expect that these SNPs in the TNF-α and PTPN22 genes might have a vital effect on the appearance of T1DM. Conventionally, association studies are applied to specific candidate genes of presumed importance in the disease. To our knowledge, no other study has so far examined the genetic variability of TNF-α or PTPN22 in Bosnia and Herzegovina subjects. Therefore, we undertook casecontrol study design to clarify whether TNF-α G-238A (rs361525), G-308A (rs1800629) and PTPN22 C1858T (rs2476601) polymorphisms correlate with increased risk of T1DM and also the clinical outcome of disease among diabetic patients of Bosnia and Herzegovina.
Experimental Procedures

Subjects
A total of 402 subjects were enrolled in this association study. The patient group consisted of randomly selected 241 subjects (male/female The relevant research ethics committee gave ethical approval (No: 11-1-08/05) for this study. All patients and control subjects were informed of the study's purpose and gave their informed consent before anonymously participating in the study.
DNA extraction and genotyping
DNA was isolated from 3 ml of peripheral blood by salting-out procedure [8] , whose concentration was spectrophotometrically measured (Biospec, Shimadzu).
The appropriate fragments of TNF-α or PTPN22 genes were amplified by polymerase chain reaction (PCR) using two sets of primersfor each gene [9, 10] :
Primers for both polymorphic sites in TNF-α contain a single base-pair mismatch adjacent to the polymorphic sites. These changes introduce a restriction site into the wild-type nucleotide sequences after amplification [9] .
The PCR mixture contained 100 ng DNA, 10 pmol of each primer, 200 μM of dNTP, 1x PCR buffer with MgCl 2 , 1 U Taq DNA polymerase (Eppendorf, Hamburg, Germany) and QH 2 O up to 25 µl. PCR was started with initial denaturation at 95ºC for 2 min, followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 60°C (TNF-α) or 62°C (PTPN22) for 30 s and extension at 72°C for 30 s. The reaction was completed by final extension at 72°C for 10 min. PCR products were checked by electrophoresis on 2.5% agarose gel containing ethidium bromide and visualized under UVC light (Alliance 4.7 UVTech, Cambridge).
The resulting PCR products (3 µL) were further digested with 4 units of appropriate restriction enzyme: MspI (Fermentas, Germany) for detection G/A SNP at TNF-α-238 locus (rs 361525, 139 bp +13 bp G allele, 152 bp A allele), NcoI (New England, BioLabs, SAD) for detection G/A SNP at TNF-α-308 locus (rs 1800629,126 bp +16 bp G allele, 142 bp A allele) and RsaI (Fermentas, Germany) for detection C/T SNP at 1858 locus of PTPN22 (rs2476601, 172 bp + 46 bp C allele, 218 bp T allele). The restriction mixture (15 µl) was incubated at 37ºC overnight. Genotype of each sample was determined by vertical electrophoresis on 10% (TNF-α) or 12% (PTPN22) poly acrylamide/bisacrylamide gel (16 cm long) containing 1x Tris-borateethylenediaminetetraacetic acid buffer. DNA fragments were stained with SYBR Gold dye (Molecular Probes, Leiden, the Netherlands) and visualized under ultraviolet light (Alliance 4.7 UVTech, Cambridge). 15% randomly selected samples were re-tested for these SNPs and obtained results fully corroborated earlier findings.
Statistical analysis
Genotype frequencies in the patient and control groups were calculated by direct counting. Webbased calculator made by Michael H. Court, (http://www.tufts.edu/˜mcourt01/useful_links.htm) was used to determine whether observed genotype frequencies were consistent with Hardy-Weinberg equilibrium (HWE). P value >0.05 were considered consistent with HWE (df=1).
Statistical analysis was performed by GraphPad Prism and Sigma Stat 3.5 (Jandell Scientific Corp. San Raphael, California, USA) software. The differences between groups were evaluated using Pearson X 2 test. When necessary, the Yates' correction was used. The level of statistical significance was set at P value less than 0.05 (two-tailed test). Odds ratios (OR) and 95% confidence intervals (CI) were calculated by a webbased OR calculator for unmatched case-control studies (http://www.hutchon.net/ConfidOR.htm).
The Kolmogorov-Smirnov test was used to evaluate normality of distribution of clinical variables. The t test was applied to compare means of normally distributed variables (N of each group should be ≥30), while the Mann-Whitney test was used for comparison of variables that are not normally distributed (N of a group could be <30).
Results
Genotypes at the two polymorphic sites in the promoter region of TNF-α and one site in the coding region of PTPN22 gene was determined in a cohort of 241 patients with T1DM and 161 healthy subjects. Genotype frequencies at these loci followed the Hardy-Weinberg equilibrium (x 2 test P values >0.05) in patients (TNF-α-238 P=0.261; TNF-α-308 P=0.985; PTPN22 P=0.511), as well as in control subjects (TNF-α-238 P=0.685; TNF-α-308 P=0.905; PTPN22 P=0.153). The achieved power at PTPN22 for controls and patients were 61% and 68%, respectively. The distribution of -238 and -308 genotype (GG, GA, AA) frequencies of TNF-α was not statistically different between patient and control groups ( Table 1 ). The minor allele (A) frequency among patients was also comparable to that of the control group ( Table 1) .
In contrast to results obtained at TNF-α polymorphic loci, distribution of CC, CT and TT genotypes at the 1858 position of the PTPN22 gene was significantly different between groups, due to higher frequency of CT and TT genotypes among subjects with T1DM (46.9%) than in controls (36.6%) ( Table 1) . Thereby, the importance of TT genotype for diabetes risk was indicated by high OR=4.533 (95% CI=1.009-20.364). The frequency of risk allele T (tryptophan containing allele) was also significantly higher in patients than in the control group (P=0.023). The overall OR for carriers of the T allele was 1.514 (95% CI=1.072-2.138).
Gender-stratified analysis of genotype distribution between patients and controls showed that there was no significant difference neither in TNF-α nor in PTPN22 gene (P>0.05, data was not shown). Considering the control group, no sex-related difference in the genotype To examine the association of the risk alleles TNF-α-238A, TNF-α-308A or PTPN22 1858T with the value of HbA1c, the whole patient group was divided according to presence or absence of the certain allele. Patients` HbA1c levels were nearly the same regardless of the presence or absence of A allele at TNF-α-238 position ( Table 2) . In contrast, patients with A allele at TNF-α-308 position had significantly higher value of HbA1c than carriers of non-risk G allele ( Table 2 , P=0.019).
The concomitant presence of the A allele at both TNF-α loci was found in only 5 out of 241 patients. They did not have worse glucose control (based on HbA1c level) than carriers of A allele at a single locus, as would be expected (Table 2) . On the other hand, the carriers of the risk (T) allele of the PTPN22 gene did not have significantly different HbA1c value compared to patients without T allele (Table 2) .
Since analyzed SNPs can influence not only the susceptibility to diabetes development (PTPN22 1858T) but also to the poor long-term glucose control (TNF-α-308A), we further analyzed their possible synergistic effects. Individuals in patient and control groups were divided according to presence or nonpresence of two risk alleles -A allele at TNF-α-308 and T allele at PTPN22 1858. A higher percent of individuals with the concomitant presence of A and T risk alleles was in patient group (12.5%) than in control group (7.4%), but without statistical significance (Pearson x 2 =3.432, P=0.064). Furthermore, this genotype-based subgroup of patients had the highest HbA1c level among patients in our study (HbA1c=9.120, t=-2.738, P=0.008, df=85) (Table 2) , suggesting the role of both genes in the effectiveness of insulin therapy. Finally, no significant association between T1DM duration and genetic variability in these polymorphic loci was observed (data was not shown).
Discussion
We performed case-control study to investigate association of TNF-α G-238A and G-308A promoter polymorphisms and PTPN22 C1858T polymorphism with T1DM in a population of participants from the central part of Bosnia and Herzegovina. It was known that testing for Hardy-Weinberg (HW) equilibrium is strongly advocated as an important quality control step in population genetic studies [11, 12] , in order to reduce the chance of false-positive associations. In our work, the genotype distribution of TNF-α and PTPN22 polymorphisms fulfilled HW criteria both in patient and control groups.
Since it has been shown that the presence of A allele at -238 and -308 loci is associated with elevated TNF-α production [13] [14] [15] , we considered GA and AA as risk genotypes that might play a role in promoting T1DM development and/or exacerbation of a diabetic state. Overall, our results suggest that two SNPs (G-238A and G-308A), located in promoter of the TNF-α gene, are not associated with the susceptibility to the development of type 1 diabetes mellitus in our study population. The majority of diabetic patients as well as healthy controls have been carriers of protective GG genotype at TNF-α-238 locus (94.2% and 90.1%, respectively), similar to reports from populations of Northern India [16] and Croatia [17] . Table 2 . Dependence of HbA1c level on the presence of risk alleles TNF-α-238A, -308A or/and PTPN22 1858T.
HbA1c -hemoglobin A1c (mean ± standard deviation) *-significantly different compared to patients without risk allele(s)
The distribution of genotype frequency at -308 polymorphic site was somewhat different than that at -238 site. Namely, it should be noted that a much higher percent of patients with the risk genotypes (GA, AA) was detected at -308 position (30.3%) than at -238 position (5.8%). Nearly the same trend in genotypes distribution at -308 and -238 is also observed among control subjects (28.6% at -308 vs 9.9% at -238). Thus, the difference between controls and patients was not significant. This lack of association between T1DM and TNF-α-308 gene variants was also found in Chile population as result of very high percent (more than 80%) of GG carriers and smaller percent (about 11%) of high risk genotype in both patients and controls [18] . However, the small number of Chilean subjects (27 per group) involved in that study must be taken into consideration in interpretation of the results.
On the other hand, the data noted in population of Bosnia and Herzegovina are not in agreement with the previously published results obtained in individuals from North India [16] , or Croatia [19] , where significant susceptibility between T1DM and TNF-αG-308A polymorphism has been detected. The difference is due to much higher percent of high-risk genotype carriers among patients in contrast to controls (38.5% vs 14.3% North India; 50.6% vs 17.6% Croatia). These discrepancies between results of different studies might be attributed to genetic heterogeneity between populations, heterogeneity in the enrollment of patients and/or a variable degree of association between an autoimmunity predisposing allele of the same gene and the disease among various populations. One of the most important genetic determinant of many autoimmune diseases is human leukocyte antigen (HLA) region. Within this region on chromosome 6p21 is located the TNF-α gene. HLA region is highly polymorphic and it is estimated to be responsible for over 50% genetic risk of developing autoimmune diabetes. Therefore, the possible linkage disequilibrium of TNF-α SNPs and HLA alleles must be taken into account in future studies.
PTPN22 1858T polymorphism has been identified as a susceptible gene variant for T1DM, but the results of numerous studies are inconsistent. To the best of our knowledge, other reports of genetic screening of PTPN22 C1858T polymorphism and its association with T1DM in a Bosnia and Herzegovina population do not exist. Thus, our study is the first study showing that PTPN22 1858T gene variant significantly contributes to the pathogenesis of autoimmune diabetes in a population from central part of Bosnia and Herzegovina. In other words, the frequency of the risk (T) allele is significantly higher among diabetic subjects (26.1%) than healthy subjects (18.9%), supporting the hypothesis that carries of T allele may have reduced capacity to down-regulate T-cell responses and may therefore be more susceptible to autoimmunity.
Recently performed meta-analysis, including 26 studies, total 16 240 T1DM patients and 17 997 controls of different ethnicities, has confirmed an association between PTPN22 1858T allele and T1DM especially in European and American populations [20] . Homozygous genotype TT is uncommon in the healthy subjects and the usual frequency is 0% (Danish), 0.5% (Croatians), 0.7% (USA Caucasians) or 0.8% (Ukrainian) [19, 21, 22] . A slightly higher frequency (1.2%) of TT genotype was found among healthy subjects of Bosnia and Herzegovina. However, among patients of Bosnia and Herzegovina the frequency of TT genotype has grown more than four-fold (5.4%). The overall odds ratio of T versus C is 1.514 in our study, while in the previously mentioned meta-analysis it was 1.948 [20] .
On the other hand, the frequency of the dominant homozygous genotype CC is higher in some other populations (USA Caucasians 83.5%, Croatians 77.1%, 72.8% Ukrainian) than we observed among subjects from central part of Bosnia and Herzegovina (63.4%) that could be attributed to different ethnicity of respondents.
Gender-stratified analysis in our study did not show an association between T1DM and the distribution of PTPN22 C1858T polymorphism. Our results are consistent with the finding observed in Dutch population [22] and not consistent with findings obtained in Ukrainian [23] and German [24] population.
Namely, in Ukrainian and German populations have been found higher frequency of TT genotype and T allele in female T1DM patients. The discrepancy between studies could be attributed to different PTPN22 T allele frequency between populations and probably smaller sample size in our study. However, we must take into account overrepresentation autoimmune diseases in women and influence of sex hormones in the disease.
In the clinical management of diabetes, HbA1c assay has been indispensable. This assay is an essential tool to determine whether a patient has achieved the main goal of therapy for diabetes: reduction and keeping of plasma glucose concentration safely as close to normal level as possible. HA1c correlates well with fasting blood glucose and it depends on the glucose levels over a previous 3-months period (mean of blood glucose and value of HbA1c have a very high coefficient of correlation R 2 =0.84). In this work we evaluated the interaction between long-term glycemic control, assessed by HbA1c, and gene polymorphisms analyzed in this study. Thereby, we presumed that TNF-α A allele at -238 and/or -308 might contribute to more difficult glycemic control, and probably a more severe disease outcome. Namely, A allele at these loci is associated with higher promoter activity resulting in elevated level of that proinflamamtory cytokine [25, 26] , which is further implicated in enhanced inflammation. Indeed, in our study patients with A allele had worse glucose regulation (higher HbA1c level) than patients with G allele. The trend in relationship between risk allele and worse glycemic control is observed at both TNF-α loci (also at PTPN22 1858 locus), but the difference reached statistical significance only at -308 locus. In contrast to that, no significant association between TNF-α-308 A allele and HbA1c level among Hungarian [27] and Croatian [17] T1DM patients was found.
Despite limitations of this study, some certain conclusions can be drawn from our results. We can summarize our results by pointing out that highproducing -238A and -308A alleles in the promoter of the TNF-α gene are not associated with the risk for the T1DM development, but are associated (TNF-α-308A) with the clinical feature of T1DM (effectiveness of glycemic control) in patients from Bosnia and Herzegovina. On the other hand, the risk allele 1858T of the PTPN22 gene is linked with autoimmune diabetes among subjects of Bosnia and Herzegovina, and could be a susceptibility gene for the disease.
